Telix Revenue Soars as Cancer Therapy Pipeline Hits Key Milestones

MELBOURNE, Australia – April 06, 2026 – Telix Pharmaceuticals has underscored its rapid ascent in the global oncology market, reporting robust first-quarter revenue growth and a series of significant advancements across its late-stage therapeutic pipeline. The dual-listed biopharmaceutical firm announced unaudited group revenue of US$230 million for the quarter ending March 31, 2026, an 11% jump from the previous quarter and a 24% increase year-over-year, signaling sustained momentum for its commercial products.

This strong financial performance, driven by the company's precision imaging agents, is providing the foundation for an ambitious strategy to develop a new generation of targeted cancer therapies. Telix reaffirmed its full-year 2026 revenue guidance of US$950 million to US$970 million, reinforcing investor confidence in its commercial execution and strategic direction.

Diagnostic Dominance Fuels Therapeutic Ambition

The engine of Telix's financial success remains its Precision Medicine business, which posted US$186 million in revenue, a 16% increase quarter-over-quarter. This growth is largely attributed to the expanding market uptake of its prostate cancer imaging agents, Illuccix® and Gozellix®. The company reported a 5% increase in U.S. dose volumes, highlighting its deepening penetration in the competitive North American market.

Dr. Christian Behrenbruch, Managing Director and Group CEO, commented on the performance, stating, "Growth accelerated across our Precision Medicine business in the first quarter... This performance reflects the growing uptake of Gozellix alongside Illuccix, contributing to market share gains underpinned by disciplined sales execution and pricing, and high-quality service delivery despite extreme North American weather conditions, an advantage of the pharmacy distribution model."

This commercial success is not just an end in itself but a crucial enabler of the company's long-term vision. With a reaffirmed research and development (R&D) budget of US$200 million to US$240 million for the year, Telix is leveraging its operational profitability to aggressively fund a diverse portfolio of high-value therapeutic candidates. This synergistic model—where successful diagnostics finance the development of corresponding therapeutics—positions Telix as a formidable, integrated player in the radiopharmaceutical space.

A Multi-Front War on Cancer

While prostate cancer remains a core focus, Telix made substantial progress across a broad therapeutic pipeline targeting some of the most challenging malignancies. The most significant milestone came from its lead prostate cancer therapy candidate, TLX591-Tx. The company announced that Part 1 of the ProstACT® Global Phase 3 study met its primary safety and dosimetry objectives, with no new safety signals observed. This critical de-risking event confirms the therapy's acceptable safety profile and its feasibility for use in combination with current standard-of-care treatments for metastatic castration-resistant prostate cancer (mCRPC). Part 2 of the trial, a randomized treatment expansion, is now enrolling patients in several countries, and Telix is engaging with the U.S. Food and Drug Administration (FDA) to include American patients.

Beyond prostate cancer, Telix is advancing its arsenal on multiple fronts:

• Brain Cancer: The company has enrolled the first patient in its IPAX-BrIGHT pivotal trial for TLX101-Tx, a therapy candidate for recurrent glioblastoma, a notoriously aggressive brain cancer. The trial is now active in Australia and parts of Europe, with this therapeutic development being closely paired with its diagnostic counterpart.

• Kidney Cancer: Telix has opened its first clinical site for the LUTEON pivotal trial of TLX250-Tx, a monotherapy aimed at treating advanced clear cell renal cell carcinoma (ccRCC), the most common and aggressive form of kidney cancer.

• Bone Metastases: To address a debilitating side effect of many advanced cancers, Telix continues to dose patients in its SOLACE Phase 1 study of TLX090-Tx, a candidate designed to treat pain from bone metastases, and has expanded the study to additional U.S. sites to accelerate recruitment.

These parallel developments underscore a strategy to build a comprehensive portfolio of radiopharmaceutical therapies, leveraging targeted radiation to attack cancer cells while minimizing damage to healthy tissue across a spectrum of diseases with high unmet need.

Navigating a Complex Global Landscape

Telix's strategy is inherently global, involving a complex dance of commercial expansion and multi-jurisdictional regulatory navigation. The company's primary imaging agent, Illuccix, is now commercially available in 21 countries, establishing a vital logistical and sales network that can be leveraged for future product launches.

This quarter saw major regulatory strides in three of the world's largest pharmaceutical markets. In the United States, Telix resubmitted its New Drug Application (NDA) for TLX101-Px (to be branded Pixclara®), an advanced imaging agent for brain cancer. In Europe, a corresponding Marketing Authorization Application (MAA) was filed for the same product, under the proposed brand name Pixlumi®. The availability of a targeted, commercially produced PET imaging agent for glioma could represent a significant advance over the current hospital-based production methods.

Perhaps most significantly for its global ambitions, Telix's NDA for its prostate imaging agent TLX591-Px was accepted for review by China's National Medical Products Administration (NMPA). This marks a critical step toward entering the vast and strategically important Chinese market.

The company is also advancing its Biologics License Application (BLA) resubmission for Zircaix® (TLX250-Px), a kidney cancer imaging agent, targeting a submission in the first half of 2026 after productive meetings with the FDA.

Fortifying Leadership for the Next Phase

To guide its next phase of growth and navigate the complexities of being a major U.S.-listed entity, Telix announced a key leadership transition as part of its board renewal process. David Gill, a life sciences executive with over 35 years of experience in senior finance and management roles, will join the board as a Non-Executive Director and is expected to be appointed Chair in due course.

Mr. Gill's deep background includes CFO and presidential roles at multiple publicly traded biopharmaceutical and medical device companies, including CTI Molecular Imaging, a pioneering radiopharmaceutical firm acquired by Siemens. His extensive experience in U.S. public company governance, capital markets, and scaling global businesses is seen as a crucial addition to the board's capabilities as Telix matures from a development-stage company into a global commercial leader. The move fortifies the company's governance structure as it continues its ambitious expansion on all fronts.